Wang Mao-ci, Wang Tai-ping, Yang Shao-ming
Rizhao Municipal Center for Disease Control and Prevention, Rizhao 276826 Shandong, China.
Zhongguo Yi Miao He Mian Yi. 2010 Jun;16(3):229-32.
To assess the effectiveness of 23-valent penumococcal polysaccharide vaccine (PenV23) and Split-Virus influenza vaccine (InfV-B) for preventing upper respiratory diseases in the aging population.
151 people aged > or =60 years who inoculated the PenV23 and InfV-B vaccines at clinics during 2005 as trial group, and 188 people aged > or =65 years didn't administered as control guoup from some comminity. On base line survey, both guoups were followed up two years after vaccination about incidence, hospitalization rate, treatment and direct medical cost.
The vaccine of PenV23 and InfV-B vaccination in upper respiratory tract infection was 60% [(odds ratio OR) = 0.35, 95% CI (0.153-0.794)] and the difference between the 2 groups was significant (P = 0.009). The people had recevied both vaccines, the mean duration of hospitalization in vaccinated vs unvaccinated control peple was 20.00 days: 24.19 days (t = 5.82, P < 0.001). Benefit-cost ratio was 4.03, and the net benefit was Yen 177994.86.
Incidence of influenza-like illness for the elderly people in the community decreased by administered PenV23 ahd InfV-B vaccine. This vaccines had high cost-benefits.
评估23价肺炎球菌多糖疫苗（PenV23）和裂解流感病毒疫苗（InfV - B）在预防老年人群上呼吸道疾病方面的有效性。
2005年期间在诊所接种PenV23和InfV - B疫苗的151名年龄≥60岁的人作为试验组，来自某社区的188名年龄≥65岁未接种疫苗的人作为对照组。在基线调查时，对两组在接种疫苗两年后随访其发病率、住院率、治疗情况及直接医疗费用。
PenV23和InfV - B疫苗接种对上呼吸道感染的预防效果为60%[比值比（OR） = 0.35，95%可信区间（0.153 - 0.794）]，两组间差异有统计学意义（P = 0.009）。接种两种疫苗的人群与未接种疫苗的对照人群相比，平均住院天数为20.00天：24.19天（t = 5.82，P < 0.001）。效益成本比为4.03，净效益为177994.86日元。
社区老年人接种PenV23和InfV - B疫苗后，流感样疾病的发病率降低。这两种疫苗具有较高的成本效益。
